Sentinel Dosing-Time for a Risk-Based Approach?
- PMID: 39582143
- DOI: 10.1002/jcph.6167
Sentinel Dosing-Time for a Risk-Based Approach?
References
-
- Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti‐CD28 monoclonal antibody TGN1412. New Eng J Med. 2006;355:1018‐1028.
-
- Panoskaltis N, McCarthy NE, Stagg AJ, et al. Immune reconstitution and clinical recovery following anti‐CD28 antibody (TGN1412)‐induced cytokine storm. Cancer Immunol Immunother. 2020;70:1127‐1142.
-
- MHRA Press Office, Press Release: Clinical trial suspension: latest findings. 2006. Accessed November 18, 2024. https://webarchive.nationalarchives.gov.uk/ukgwa/20141206175918/http://w....
-
- Horvath CJ, Milton MN. The TeGenero incident and the Duff Report conclusions: A series of unfortunate events or an avoidable event? Toxicol Pathol. 2009;37:372‐383.
-
- Tabrizi MA, Roskos LK. Preclinical and clinical safety of monoclonal antibodies. Drug Disc Today. 2007;12:540‐547.
LinkOut - more resources
Full Text Sources